Form 4 Filing for REVELATION BIOSCIENCES, INC.

James Rolke, Chief Executive Officer and Director of REVELATION BIOSCIENCES, INC. (REVB), reported a disposition of 10,115 shares of Common Stock on April 30, 2026. The shares were sold at a weighted average price of $1.13 per share, with individual transactions ranging from $1.12 to $1.14. This sale was conducted to cover required tax withholdings arising from the vesting of restricted stock awards, as indicated by footnote F1. The transaction was mandatory, and Mr. Rolke did not exercise investment discretion. Following this transaction, Mr. Rolke directly owns 214,738 shares of Common Stock.